FY2024 EPS Estimates for OptiNose Raised by HC Wainwright

OptiNose, Inc. (NASDAQ:OPTN - Free Report) - Equities research analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of OptiNose in a research note issued on Wednesday, November 13th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($0.18) per share for the year, up from their prior estimate of ($0.22). HC Wainwright currently has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for OptiNose's current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for OptiNose's FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.23 EPS and FY2028 earnings at $0.35 EPS.

Separately, Piper Sandler decreased their target price on OptiNose from $3.00 to $1.00 and set an "overweight" rating on the stock in a research note on Wednesday.

OptiNose Price Performance

NASDAQ OPTN traded down $0.02 during trading on Friday, reaching $0.44. The company's stock had a trading volume of 1,119,462 shares, compared to its average volume of 737,202. The stock has a market capitalization of $65.61 million, a PE ratio of -1.55 and a beta of -0.07. The firm has a fifty day moving average of $0.74 and a 200 day moving average of $0.95. OptiNose has a one year low of $0.41 and a one year high of $2.10.

Hedge Funds Weigh In On OptiNose

Institutional investors and hedge funds have recently modified their holdings of the company. Stonepine Capital Management LLC purchased a new position in OptiNose during the second quarter valued at $2,444,000. Great Point Partners LLC lifted its position in OptiNose by 56.2% during the second quarter. Great Point Partners LLC now owns 13,727,097 shares of the company's stock valued at $14,276,000 after purchasing an additional 4,940,779 shares in the last quarter. XTX Topco Ltd purchased a new position in OptiNose during the second quarter valued at $88,000. Squarepoint Ops LLC raised its holdings in OptiNose by 173.7% during the second quarter. Squarepoint Ops LLC now owns 171,610 shares of the company's stock valued at $178,000 after acquiring an additional 108,903 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in OptiNose by 2.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company's stock valued at $3,037,000 after acquiring an additional 81,233 shares during the period. 85.60% of the stock is currently owned by hedge funds and other institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.